1. A phase I dose‐escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC‐223 in patients with advanced solid tumors or multiple myeloma. Issue 19 (15th July 2015) Authors: Bendell, Johanna C.; Kelley, Robin K.; Shih, Kent C.; Grabowsky, Jennifer A.; Bergsland, Emily; Jones, Suzanne; Martin, Thomas; Infante, Jeffrey R.; Mischel, Paul S.; Matsutani, Tomoo; Xu, Shuichan; Wong, Lilly; Liu, Yong; Wu, Xiaoling; Mortensen, Deborah S.; Chopra, Rajesh; Hege, Kristen; Munste... Journal: Cancer Issue: Volume 121:Issue 19(2015) Page Start: 3481 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non–small cell lung cancer: A randomized, placebo‐controlled phase 2 trial with correlated serum proteomic signatures. Issue 11 (12th April 2018) Authors: Spigel, David R.; Burris, Howard A.; Greco, F. Anthony; Shih, Kent C.; Gian, Victor G.; Lipman, Andrew J.; Daniel, Davey B.; Waterhouse, David M.; Finney, Lindsey; Heymach, John V.; Hainsworth, John D. Journal: Cancer Issue: Volume 124:Issue 11(2018) Page Start: 2355 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗